RESUMO
Noben (idebenone) at a dose of 120 mg per day for six months was used in the treatment of 35 patients aged 60-86 years with Alzheimer's-type dementia, mixed dementia, and memory impairments not reaching the stage of dementia. Patients were assessed on the basis of data from somatic, neurological, and psychiatric investigations, as well as neuropsychological testing and a series of psychometric and other scales and tests, before and after treatment. Significant improvements in patients' conditions on the MMSE were seen in patients with mild and moderate dementia. Improvements in daily activities were obtained in 27% of patients. Neuropsychological investigations demonstrated improvements in short-term and long-term memory and attention, with improvements in speech functions, performance of kinesthetic, spatial, and dynamic praxis tests, and in visuospatial gnosis, thought, and writing. On the CGI scale, positive treatment effects were obtained in 37% of patients, while 48% of patients remained in a stable state.
Assuntos
Antioxidantes/uso terapêutico , Transtornos Cognitivos/tratamento farmacológico , Demência/tratamento farmacológico , Ubiquinona/análogos & derivados , Idoso , Idoso de 80 Anos ou mais , Antioxidantes/administração & dosagem , Atenção/efeitos dos fármacos , Atenção/fisiologia , Cognição/efeitos dos fármacos , Cognição/fisiologia , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/etiologia , Demência/complicações , Demência/diagnóstico , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Humanos , Masculino , Memória/efeitos dos fármacos , Memória/fisiologia , Pessoa de Meia-Idade , Testes Neuropsicológicos , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Ubiquinona/administração & dosagem , Ubiquinona/uso terapêuticoRESUMO
Noben (idebenone) was administered in dosage 120 mg during 6 months to 35 patients, aged from 60 to 86 years, with dementia, Alzheimer's type and mixed type, and with memory disturbances which did not reach the level of dementia. The assessment of patient's state before and after treatment was based on the results of somatic, neurological and psychiatric examination as well as neuropsychological testing and using of psychometrical and other scales. The significant improvement on the MMSE scale was found in patients with mild and moderate dementia. The improvement of daily activity was observed in 27% of patients. The neuropsychological study revealed the improvement of short-term and delayed memory and attention, speech functions, the performance on kinesthetic, spatial and dynamic praxis tests, visual-spatial gnosis, reasoning and writing. The positive therapeutic effect assessed by the CGI scale was observed in 37% of patients, the stable state--in 48%.
